Phospholipase D2:A biomarker for stratifying disease severity in acute pancreatitis?  

作　　者：Zhi-Hui Wang Jia-Hui Lv Yun Teng Ntim Michael Yi-Fan Zhao Min Xia Bin Wang 

机构地区：[1]Liaoning Provincial Key Laboratory of Cerebral Diseases,College of Basic Medical Sciences,National-Local Joint Engineering Research Center for Drug Research and Development of Neurodegenerative Diseases,Dalian Medical University,Dalian 116000,Liaoning Province,China [2]The Second Affiliated Hospital,Dalian Medical University,Dalian 116000,Liaoning Province,China [3]Department of Physiology,School of Medicine and Dentistry,Kwame Nkrumah University of Science and Technology,Kumasi 00233,Ashanti,Ghana [4]Department of Anesthesiology,General Hospital of The Yangtze River Shipping,Wuhan Brain Hospital,Wuhan 430012,Hubei Province,China

出　　处：《World Journal of Gastroenterology》2025年第11期6-13,共8页世界胃肠病学杂志(英文)

基　　金：Supported by National Natural Sciences Foundation of China,No.82301700;Liaoning Province Natural Science Foundation Project,No.2024-MS-157;Youth Talent Cultivation Fund Key Project of Dalian Medical University;Scientific Research Projects from Wuhan Municipal Health Commission,No.WX23Z26;Science and Technology of Liaoning Province,No.2023-MS-266.

摘　　要：In this editorial,we critically evaluate the recent article by Niu et al,which ex-plores the potential of phospholipase D2(PLD2)as a biomarker for stratifying disease severity in acute pancreatitis(AP).AP is a clinically heterogeneous inflam-matory condition that requires reliable biomarkers for early and accurate classi-fication of disease severity.PLD2,an essential regulator of neutrophil migration and inflammatory responses,has emerged as a promising candidate.Although current biomarkers such as C-reactive protein and procalcitonin provide general indications of inflammation,they lack specificity regarding the molecular mechanisms underlying AP progression.Recent studies,including the research conducted by Niu et al,suggest an inverse correlation between PLD2 expression and AP severity,offering both diagnostic insights and mechanistic understanding.This editorial critically evaluates the role of PLD2 as a biomarker in the broader context of AP research.Evidence indicates that decreased levels of PLD2 are associated with increased neutrophil chemotaxis and cytokine release,con-tributing to pancreatic and systemic inflammation.However,several challenges remain,including the need for large-scale validation and functional studies to establish causation,and standardization of measurement protocols.Additionally,further investigation into the temporal dynamics of PLD2 expression and its variability across diverse populations is warranted.Looking ahead,PLD2 holds the potential to revolutionize AP management by integrating molecular diagnostics with precision medicine.The utilization of large-scale multi-omics approaches and advancements in diagnostic platforms could position PLD2 as a fundamental biomarker for early diagnosis,prognosis,and potentially therapeutic targeting.While promising,it is crucial to conduct critical evaluations and rigorous validations of PLD2’s role to ensure its efficacy in improving patient outcomes.

关 键 词：Phospholipase D2 Acute pancreatitis BIOMARKER Inflammatory response Severity diagnosis 

分 类 号：R57[医药卫生—消化系统]